Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GLR2053
- Development stage
- Phase 1
- Lead developer
- Gan & Lee Pharmaceuticals
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
GLR2053 is an investigational, orally administered proteolysis-targeting chimera (PROTAC) designed to target and degrade the transcription factor STAT6. Developed by Gan & Lee Pharmaceuticals, GLR2053 is a small-molecule heterobifunctional degrader that binds STAT6 on one end and recruits the E3 ubiquitin ligase cereblon (CRBN) on the other. This recruitment forms a STAT6–PROTAC–CRBN ternary complex, tagging STAT6 with ubiquitin for subsequent proteasomal degradation. In late October 2026, China's National Medical Products Administration (NMPA) granted clinical trial approval (IND) for GLR2053 tablets for the treatment of atopic dermatitis.
02
Targets
CRBN (Cereblon)STAT6 (Signal Transducer and Activator of Transcription 6)
Beyond the preview
Go deeper on GLR2053.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GLR2053.